← All trials
NCT01355471
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Nov 1, 2011
- Completion date
- Jan 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 293
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GaldermaLead sponsor
- Kirk Barber Research Inc.Overall official - principal investigator
- Grekin Skin InstituteOverall official - principal investigator
- J&S Studies Inc.Overall official - principal investigator
- Nexus Clinical ResearchOverall official - principal investigator
- Oregon Dermatology and Research CenterOverall official - principal investigator
- Burke Pharmaceutical ResearchOverall official - principal investigator
- Meda Phase, Inc.Overall official - principal investigator
- Palmetto Clinical Trial Services, LLCOverall official - principal investigator
- Premier Research GroupOverall official - principal investigator
- Baumann Cosmetic & Research InstituteOverall official - principal investigator
- GaldermaStudy chair
- NewLab Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.